398 related articles for article (PubMed ID: 37534876)
61. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
[TBL] [Abstract][Full Text] [Related]
62. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
63. A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study.
Kwon JW; Park EJ; Jung SY; Sohn HS; Ryu H; Suh HS
J Dent Res; 2015 Sep; 94(9 Suppl):212S-9S. PubMed ID: 26001708
[TBL] [Abstract][Full Text] [Related]
64. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
65. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
66. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records.
Taquet M; Geddes JR; Husain M; Luciano S; Harrison PJ
Lancet Psychiatry; 2021 May; 8(5):416-427. PubMed ID: 33836148
[TBL] [Abstract][Full Text] [Related]
67. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
68. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
69. Outcomes of SARS-CoV-2-Positive Youths Tested in Emergency Departments: The Global PERN-COVID-19 Study.
Funk AL; Florin TA; Kuppermann N; Tancredi DJ; Xie J; Kim K; Neuman MI; Ambroggio L; Plint AC; Mintegi S; Klassen TP; Salvadori MI; Malley R; Payne DC; Simon NJ; Yock-Corrales A; Nebhrajani JR; Chaudhari PP; Breslin KA; Finkelstein Y; Campos C; Bergmann KR; Bhatt M; Ahmad FA; Gardiner MA; Avva UR; Shah NP; Sartori LF; Sabhaney VJ; Caperell K; Navanandan N; Borland ML; Morris CR; Gangoiti I; Pavlicich V; Kannikeswaran N; Lunoe MM; Rino PB; Kam AJ; Cherry JC; Rogers AJ; Chong SL; Palumbo L; Angelats CM; Morrison AK; Kwok MY; Becker SM; Dixon AC; Poonai N; Eckerle M; Wassem M; Dalziel SR; Freedman SB;
JAMA Netw Open; 2022 Jan; 5(1):e2142322. PubMed ID: 35015063
[TBL] [Abstract][Full Text] [Related]
70. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
Nordström P; Ballin M; Nordström A
Lancet Infect Dis; 2022 Jun; 22(6):781-790. PubMed ID: 35366962
[TBL] [Abstract][Full Text] [Related]
71. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis.
Curtis JR; Xi J; Westfall AO; Cheng H; Lyles K; Saag KG; Delzell E
Med Care; 2009 Mar; 47(3):334-41. PubMed ID: 19194337
[TBL] [Abstract][Full Text] [Related]
72. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
73. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
74. Comparative incidence of early and late bloodstream and respiratory tract co-infection in patients admitted to ICU with COVID-19 pneumonia versus Influenza A or B pneumonia versus no viral pneumonia: wales multicentre ICU cohort study.
Pandey M; May A; Tan L; Hughes H; Jones JP; Harrison W; Bradburn S; Tyrrel S; Muthuswamy B; Berry N; Pugh R; Sutton D; Campbell A; Morgan M
Crit Care; 2022 Jun; 26(1):158. PubMed ID: 35655224
[TBL] [Abstract][Full Text] [Related]
75. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
76. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge.
Polinski JM; Weckstein AR; Batech M; Kabelac C; Kamath T; Harvey R; Jain S; Rassen JA; Khan N; Schneeweiss S
JAMA Netw Open; 2022 Mar; 5(3):e222959. PubMed ID: 35297969
[TBL] [Abstract][Full Text] [Related]
77. Collateral effects of the COVID-19 pandemic on endocrine treatments for breast and prostate cancer in the UK: a cohort study.
Barclay NL; Català M; Jödicke AM; Prieto-Alhambra D; Newby D; Delmestri A; Man WY; Serrano ÀR; Moncusí MP;
Ther Adv Med Oncol; 2024; 16():17588359241253115. PubMed ID: 38832300
[TBL] [Abstract][Full Text] [Related]
78. Rethinking Immunological Risk: A Retrospective Cohort Study of Severe SARS-Cov-2 Infections in Individuals With Congenital Immunodeficiencies.
Nguyen AA; Habiballah SB; LaBere B; Day-Lewis M; Elkins M; Al-Musa A; Chu A; Jones J; Fried AJ; McDonald D; Hoytema van Konijnenburg DP; Rockowitz S; Sliz P; Oettgen HC; Schneider LC; MacGinnitie A; Bartnikas LM; Platt CD; Ohsumi TK; Chou J
J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3391-3399.e3. PubMed ID: 37544429
[TBL] [Abstract][Full Text] [Related]
79. Prepandemic Physical Activity and Risk of COVID-19 Diagnosis and Hospitalization in Older Adults.
Muñoz-Vergara D; Wayne PM; Kim E; Lee IM; Buring JE; Manson JE; Sesso HD
JAMA Netw Open; 2024 Feb; 7(2):e2355808. PubMed ID: 38349654
[TBL] [Abstract][Full Text] [Related]
80. Identification of drugs associated with reduced severity of COVID-19 - a case-control study in a large population.
Israel A; Schäffer AA; Cicurel A; Cheng K; Sinha S; Schiff E; Feldhamer I; Tal A; Lavie G; Ruppin E
Elife; 2021 Jul; 10():. PubMed ID: 34313216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
